These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 1619015

  • 1. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.
    Clemmons DR, Smith-Banks A, Underwood LE.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):234-8. PubMed ID: 1619015
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously.
    Kupfer SR, Underwood LE, Baxter RC, Clemmons DR.
    J Clin Invest; 1993 Feb; 91(2):391-6. PubMed ID: 7679407
    [Abstract] [Full Text] [Related]

  • 3. Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adults.
    Young SC, Underwood LE, Celniker A, Clemmons DR.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):603-8. PubMed ID: 1379258
    [Abstract] [Full Text] [Related]

  • 4. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
    Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
    [Abstract] [Full Text] [Related]

  • 5. Treatment of obese, diet-restricted subjects with growth hormone for 11 weeks: effects on anabolism, lipolysis, and body composition.
    Snyder DK, Clemmons DR, Underwood LE.
    J Clin Endocrinol Metab; 1988 Jul; 67(1):54-61. PubMed ID: 3379136
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T, Jørgensen JO, Jakobsen G, Hansen BL, Christiansen JS.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [Abstract] [Full Text] [Related]

  • 10. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [Abstract] [Full Text] [Related]

  • 11. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
    Chapman IM, Hartman ML, Pezzoli SS, Harrell FE, Hintz RL, Alberti KG, Thorner MO.
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
    [Abstract] [Full Text] [Related]

  • 12. Five weeks of insulin-like growth factor-I treatment does not alter glucose kinetics or insulin sensitivity during a hyperglycemic clamp in older women.
    Braun B, Friedlander AL, Pollack M, Butterfield GE, Marcus R, Hoffman AR.
    Metabolism; 2003 Sep; 52(9):1182-90. PubMed ID: 14506625
    [Abstract] [Full Text] [Related]

  • 13. Use of growth hormone and insulin-like growth factor I in catabolism that is induced by negative energy balance.
    Clemmons DR.
    Horm Res; 1993 Sep; 40(1-3):62-7. PubMed ID: 8300052
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Insulin-like growth factor-I and growth hormone have different effects on serum lipoproteins and secretion of lipoproteins from cultured rat hepatocytes.
    Sjöberg A, Oscarsson J, Olofsson SO, Edén S.
    Endocrinology; 1994 Oct; 135(4):1415-21. PubMed ID: 7925103
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.
    Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER.
    J Clin Invest; 1994 Sep; 94(3):1126-33. PubMed ID: 8083353
    [Abstract] [Full Text] [Related]

  • 18. The effects of subcutaneous insulin-like growth factor-I infusion in insulin-dependent diabetes mellitus.
    Bach MA, Chin E, Bondy CA.
    J Clin Endocrinol Metab; 1994 Oct; 79(4):1040-5. PubMed ID: 7525624
    [Abstract] [Full Text] [Related]

  • 19. Recombinant human insulin-like growth factor I, recombinant human growth hormone, and sex steroids: effects on markers of bone turnover in humans.
    Mauras N, Doi SQ, Shapiro JR.
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2222-6. PubMed ID: 8964855
    [Abstract] [Full Text] [Related]

  • 20. Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury.
    Hatton J, Kryscio R, Ryan M, Ott L, Young B.
    J Neurosurg; 2006 Dec; 105(6):843-52. PubMed ID: 17405254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.